INTRODUCTION
============

Chronic low-grade systemic inflammation is a hallmark of obesity ([@B16]). As adipose tissue expands, it is characterized by enlarged adipocytes and macrophage accumulation, resulting in increased circulating leptin, pro-inflammatory cytokines \[interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α)\] and chemokines \[monocyte chemoattractant protein-1 (MCP-1)\], and lower adiponectin levels ([@B29]). These factors, indicative of chronic systemic low-grade inflammation, are believed to be involved in the pathogenesis of cardiovascular disease ([@B26]), insulin resistance and type 2 diabetes ([@B12]). Potential mechanisms linking obesity-associated low-grade inflammation and metabolic dysfunction include activation of cytokine or toll-like receptor signaling pathways which can access cellular targets directly or via chaperoning molecules. Consequently, three prominent kinases, JNK, IKK, and PKR, downstream of these signaling pathways have important roles in relaying stress signals throughout the cell ([@B16]).

Interventions which reduce adipose tissue mass such as low-calorie diet (LCD; [@B11]; [@B9]) or bariatric surgery ([@B4]) generally result in decreased systemic and local adipose tissue inflammation. However, the majority of these investigations have been performed in obese individuals ([@B11]; [@B9]; [@B4]; [@B10]; [@B32]; [@B15]). Given that overweight subjects have a strong tendency to transition to obesity, identifying whether inflammation perturbations occur during the overweight period may be clinically relevant and is currently not known ([@B30]; [@B19]). In addition, calorie restriction (CR), a dietary intervention that delivers reduced calories while maintaining proper nutrition has potent anti-inflammatory effects in primates ([@B22]) and in humans self-prescribing CR diets ([@B13]). The anti-inflammatory effects of CR could be mediated by one or more of the following CR-induced changes; reduced adiposity and secretion of pro-inflammatory mediators, reduced oxidative stress, and increased insulin sensitivity.

The Pennington CALERIE study was a 24-week study in young, overweight adults testing the hypothesis that CR improves biomarkers of longevity ([@B17]). We have previously found that fasting insulin and core body temperature were reduced with CR while dehydroepiandrosterone sulfate (DHEA-S) wasunchanged([@B17]). Anexploratory endpoint of the study was to test the hypothesis that 24 weeks of moderate CR (25%) would reduce markers of systemic inflammation and attenuate expression of pro-inflammatory genes in subcutaneous adipose tissue. We hypothesized that overweight individuals would have increased systemic and adipose tissue inflammation gene expression, which would be reduced by a 25% energy deficit by diet and/or aerobic exercise.

MATERIALS AND METHODS {#s1}
=====================

ETHICS STATEMENT
----------------

This study was conducted according to the principles expressed in the declaration of Helsinki. The study was approved by the Pennington Biomedical Research Center IRB and the Data Safety Monitoring Board of CALERIE. All participants provided written informed consent for the collection of samples and subsequent analysis.

PARTICIPANTS
------------

Of the 599 individuals screened for the study, 551 were excluded (460 were ineligible; 91 withdrew during screening; Figure [1](#F1){ref-type="fig"}). Thirty-five overweight \[25 ≤ body mass index (BMI) \< 30\] but otherwise healthy men (25 to \< 50 years) and pre-menopausal women (25 to \< 45 years) from the Pennington CALERIE study are included in this analysis ([@B17]). Subject eligibility was assessed in three screening visits and with comprehensive testing. Participants were excluded if they smoked, exercised more than twice per week, were pregnant, lactating or post-menopausal, had a personal history of obesity (BMI never greater than 32 kg/m^2^), cardiovascular disease, diabetes, or regularly used medications (except birthcontrol). Detailsof the screening process and study population have been extensively described ([@B17]). A copy of the full study protocol can be obtained at [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

![**Flow of all participants through the Phase 1 CALERIE trial in Baton Rouge and the subset of subjects with inflammatory assessments**. Note the fourth group (low-calorie group highlighted in gray) was excluded from the inflammatory marker analysis.](fgene-03-00058-g001){#F1}

STUDY DESIGN
------------

Following a 5-week baseline period, subjects were randomized into one of four groups for 24 weeks: Control = healthy weight-maintenance diet based on the American Heart Association (AHA) Step 1 guidelines. (5M/6F), CR = 25% CR from baseline energy requirements (6M/6F), caloric restriction + exercise (CR + EX) = 12.5% CR and 12.5% increase in exercise energy expenditure (5M/7F). The study also included a fourth group (LCD) however since the goal of this treatment group was to achieve a specific weight loss followed by weight maintenance (and not to sustain a defined level of CR), this group was excluded from the inflammation analyses.

INTERVENTIONS
-------------

Individualized energy intakes were prescribed from two consecutive measures of energy expenditure by doubly labeled water at baseline ([@B25]). During 3 weeks at baseline and weeks 1--12 and 22--24 of the intervention, participants consumed a diet based on the AHA guidelines, 30% calories from fat, 15% from protein, and 55% from carbohydrate. The diets were prepared by the Metabolic Kitchen at the Pennington Biomedical Research Center. For weeks 13--22 participants followed their assigned dietary prescription by self-selection. Dietary intake and body weight were monitored weekly to ensure compliance. CR and Control participants were required to continue their usual pattern of physical activity throughout the study while participants in CR + EX increased their energy expenditure by 12.5% above baseline through structured supervised aerobic exercise sessions, 5 days/week according to an individualized exercise prescription ([@B25]).

CLINICAL ASSESSMENTS
--------------------

Body composition by dual x-ray absorptiometry (Hologics QDR 4500A, Bedford, MA, USA), abdominal fat distribution by multi-slice computed tomography (GE Light Speed, General Electric, Milwaukee, WI, USA) and fasting blood and adipose tissue biopsies were collected during a 5-day inpatient stay at baseline and 24 weeks after the intervention ([@B25]). Insulin sensitivity (Si) and acute insulin response to glucose (AIRg) were determined by the modified frequently sampled intravenous glucose tolerance test ([@B17]) at baseline and 24 weeks after the intervention. All clinical investigators conducting clinical assessments with the exception of the study physician were blinded to the treatment assignment.

BIOCHEMICAL ASSAYS
------------------

Highly sensitive C-reactive protein (hsCRP) was determined by chemiluminescent immunoassay (Immulite 2000^TM^, Siemens Healthcare Diagnostics, Deerfield, IL, USA); TNF-α and IL-6 by immunoassay (Luminex 100^TM^ , Luminex Corp., Austin, TX, USA); and leptin and adiponectin concentrations by radioimmunoassay (Linco Research Inc., St Charles, MO, USA).

### Tissue collection and gene expression analysis

Approximately, 350 mg of subcutaneous adipose tissue was collected from the abdomen (5 cm to left/right of the umbilicus) using a Bergstrom needle. Repeat biopsies were obtained no less than 1 cm from the previous biopsy incision site, in compliance with standard clinical practice at our Center. Fat cell size was determined by the Multisizer-3 counter (Beckman Coulter, Fullerton, CA, USA) as previously described ([@B18]). RNA from \~100 mg of tissue was isolated by column purification (Qiagen, Valencia, CA, USA) and yield determined by spectrophotometry (NanoDrop Technologies, Wilmington, DE, USA). From each RNA sample, 200 ng was reverse transcribed to cDNA using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). Relative quantification of mRNA expression was analyzed using ABI PRISM 7900 (Applied Biosystems, Branchburg, NJ, USA) and custom Taqman gene expression micro fluidic cards for TNF-α (Hs00174128_m1), IL-6 (Hs00985639_m1), macrophage marker (CD68, Hs00154355_m1), macrophage migration inhibitory factor (MIF, Hs00236988_g1), MCP-1 (Hs00234140_m1), plasminogen activator inhibitor-1 (PAI-1, Hs01126603_m1), and adiponectin (Hs00605917_m1). Samples were run in triplicate and expression levels were normalized to cyclophilin B (Hs00168719_m1). Cyclophilin B was not changed by treatment in either group (CR: *p* = 0.35, CR + EX: *p* = 0.62, Control: *p* = 0.76) and there was no treatment effect (*p* = 0.37).

STATISTICAL ANALYSES
--------------------

Data are presented as means ± SEM. SAS Version 9.12 (SAS Institute, Cary, NC, USA) was used for analysis. The change and percent change from baseline to month 6 was calculated for all variables, and between group differences (CR, CR + EX, Control) were tested by analysis of covariance with baseline values included in the model as covariates. Statistical significance for all multiple comparisons was adjusted using Tukey--Kramer to avoid type I errors. Statistical significance was considered when *p* \< 0.05.

RESULTS
=======

SUBJECT CHARACTERISTICS
-----------------------

At baseline the groups did not differ with respect to demographic data, body weight, adiposity, or insulin sensitivity (Table [1](#T1){ref-type="table"}). There were no associations between body weight, percent body fat, abdominal visceral fat mass, subcutaneous fat cell size, or insulin sensitivity and inflammation gene expression.

###### 

Effect of caloric restriction alone and with exercise on body composition, insulin sensitivity, and systemic markers of inflammation.

                                             Control (5M/6F)   CR (6M/6F)   CR + EX (5M/7F)                                                          
  ------------------------------------------ ----------------- ------------ ----------------- --------------------------------------- -------------- --------------------------------------
  Demographics                                                                                                                                       
  Age (year)                                 37.7 ± 2.2        --           38.4 ± 1.6        --                                      35.5 ± 1.6     --
  BMI (kg/m^2^)                              27.6 ± 2.0        --1 ± 1      27.8 ± 1.4        --10 ± 1                                27.5 ± 1.6     --10 ± 1
  Body composition and insulin sensitivity                                                                                                           
  Weight (kg)                                82.3 ± 2.9        --1 ± 1      81.2 ± 3.3        --10 ± 1[\*](#T1fn01){ref-type="fn"}    82.1 ± 3.1     --10 ± 1[\*](#T1fn01){ref-type="fn"}
  FM (kg)                                    25.5 ± 1.2        --2 ± 3      24.9 ± 1.8        --24 ± 3[\*](#T1fn01){ref-type="fn"}    26.4 ± 1.7     --25 ± 3[\*](#T1fn01){ref-type="fn"}
  VAT (kg)                                   2.9 ± 0.4         --2 ± 4      3.2 ± 0.5         --28 ± 4[\*](#T1fn01){ref-type="fn"}    2.8 ± 0.4      --27 ± 3[\*](#T1fn01){ref-type="fn"}
  Fat cell size (μl)                         0.73 ± 0.05       4 ± 7        0.65 ± 0.05       --20 ± 5[\*](#T1fn01){ref-type="fn"}    0.70 ± 0.04    --26 ± 6[\*](#T1fn01){ref-type="fn"}
  Insulin sensitivity (Si)                   2.8 ± 1.2         1 ± 11       3.3 ± 1.7         40 ± 20                                 3.4 ± 0.4      66 ± 22[\*](#T1fn01){ref-type="fn"}
  AIRg                                       750 ± 135         --17 ± 10    815 ± 136         --35 ± 9                                729 ± 175      --36 ± 9[\*](#T1fn01){ref-type="fn"}
  Glucose (mg/dl)                            93 ± 2            3.0 ± 1.5    91 ± 3            --0.4 ± 1.3                             93 ± 27        7.7 ± 8.5
  Insulin (μU/ml)                            12 ± 4            0.01 ± 8.4   9 ± 1             --28.8 ± 6.3                            10 ± 1         --26.4 ± 12.5
  Serum inflammatory markers                                                                                                                         
  Adiponectin (ng/ml)                        2997 ± 297        6 ± 4        3253 ± 302        14 ± 3                                  3440 ± 270     7 ± 4
  TNF-α (pg/ml)                              8.0 ± 1.4         44 ± 11      8.5 ± 2.0         64 ± 31                                 7.2 ± 1.7      79 ± 43
  IL-6 (pg/ml)                               145.9 ± 59.5      9 ± 14       66.5 ± 20.2       44 ± 21                                 131.5 ± 42.4   5 ± 8
  Leptin (ng/ml)                             19.3 ± 3.8        --2 ± 8      14.3 ± 3.1        --39 ± 10[\*](#T1fn01){ref-type="fn"}   18.3 ± 3.7     --52 ± 8[\*](#T1fn01){ref-type="fn"}
  CRP (mg/l)                                 0.30 ± 0.08       --27 ± 8     0.25 ± 0.07       29 ± 53                                 0.15 ± 0.03    --27 ± 8[\*](#T1fn01){ref-type="fn"}
  Gene expression (mRNA;AU)                                                                                                                          
  Adiponectin                                0.84 ± 0.06       --6 ± 6      0.71 ± 0.04       11 ± 11                                 0.94 ± 0.09    36 ± 47
  IL-6                                       4.00 ± 0.53       19 ± 25      3.87 ± 0.74       91 ± 31                                 12.30 ± 5.98   358 ± 349
  TNF-α                                      1.28 ± 0.22       30 ± 25      1.99 ± 0.35       --3 ± 26                                1.87 ± 0.27    42 ± 30
  CD68                                       0.63 ± 0.17       10 ± 17      0.99 ± 0.28       --8 ± 22                                0.60 ± 0.06    31 ± 33
  MIF                                        0.76 ± 0.08       --2 ± 9      0.74 ± 0.09       --8 ± 11                                0.86 ± 0.10    23 ± 38
  MCP-1                                      1.11 ± 0.25       20 ± 14      1.59 ± 0.37       7 ± 9                                   1.94 ± 0.43    111 ± 126
  PAI-1                                      2.40 ± 0.63       --31 ± 27    1.98 ± 0.81       208 ± 192                               2.04 ± 0.50    --22 ± 50

Baseline data (BL) and the change from baseline (expressed as a percent) are reported by treatment group (mean ± SEM). Insulin sensitivity was measured by frequently sampled glucose tolerance test.This table presents data on serum and mRNA adipose tissue expression of inflammatory mediators. Relative quantity of mRNA was determined from delta-delta CT method, where cyclophilin B was the reference gene. CR, caloric restriction; CR

\+

EX, caloric restriction

\+

exercise; BMI, body mass index; FM, fat mass; VAT, visceral adipose tissue; TNF-α, tumor necrosis factor-alpha; IL-6, interleukin 6; CRP, c-reactive protein; MCP-1, monocyte chemoattractant protein-1; MIF, macrophage migration inhibitory factor; PAI-1, plasminogen activator inhibitor-1.

Denotes change is significantly different from baseline, p \< 0.05.

### Effects of CR on body weight, body composition, insulin sensitivity

As previously reported ([@B17]), 25% energy deficit by diet alone (CR) or diet plus exercise (CR + EX) resulted in similar and significant reductions in body weight, fat mass, and abdominal visceral fat (Table [1](#T1){ref-type="table"}). There was an improvement in insulin sensitivity however it only reached significance in CR + EX.

### Effects of CR on markers of systemic inflammation and expression of inflammation-related genes in subcutaneous adipose tissue

Consistent with the loss of fat mass, there was a significant decrease in serum leptin concentrations in CR and CR + EX (Table [1](#T1){ref-type="table"} ). We also observed a significant increase in IL-6 with CR, however, this effect was driven by one subject who had a 477% increase in IL-6 concentrations. When this subject was omitted from the analysis, the effect was no longer significant. Serum levels of hsCRP and TNF-α did not change from baseline in CR however hsCRP was significantly reduced in CR + EX (Table [1](#T1){ref-type="table"} ).

There was no change in the relative mRNA level for any of the genes measured: IL-6, TNF-α, CD68, MIF, MCP-1, adiponectin, PAI-1 with the 24-week intervention (Figure [2](#F2){ref-type="fig"}). The percent change in weight, fat mass, visceral fat mass, abdominal adipocyte size, or insulin sensitivity was not related to the percent change mRNA expression of any inflammatory genes.

![**Effect of a 25% energy deficit by diet (CR) or diet in conjunction with exercise (CR + EX) on the adipose tissue gene expression of adipokines**. Gene expression shown normalized to *cyclophilin B*. Black bar: Control group; light gray bar: CR group; dark gray bar: CR + EX group. Data are mean ± SEM.](fgene-03-00058-g002){#F2}

Given the lack of difference between CR and CR + EX, we pooled the two groups and tested the hypothesis that CR/CR + EX would decrease inflammation versus controls. We did not detect any differences between CR/CR + EX and controls in either serum markers or gene expression (data not shown).

DISCUSSION
==========

In this study, overweight subjects completed a 24-week intervention producing a 25% energy deficit by diet alone (CR) or diet in conjunction with structured supervised exercise (CR + EX). The two intervention groups had similar reductions in body weight, total fat mass, and visceral fat and a wide range of circulating and gene expression inflammation markers were measured pre- and post-intervention. Contrary to our hypothesis, CR did not reduce circulating inflammatory markers or inflammation gene expression in subcutaneous adipose tissue. Furthermore CR + EX did not promote an anti-inflammatory response aside from a small, albeit significant lowering of hsCRP.

Several randomized controlled trials have been conducted to test the impact of weight loss by diet and/ or exercise on low-grade inflammation in obesity ([@B11]; [@B9]; [@B8], [@B7]; [@B3]; [@B24]; [@B27]; [@B5]). The consensus from these studies is that a threshold for weight loss (i.e., 10%) may be necessary to elicit an improvement in the inflammatory state ([@B14]). For example, a 12-week study found that serum markers (MIP-1α, IL-15) were reduced in *obese* subjects if weight loss exceeded 14.5% regardless of the type of intervention (diet or diet with exercise; [@B7]). However, mRNA expression of pro-inflammatory cytokines (IL-6 and TNFα) and macrophage markers (CD68 and MCP-1) were not altered. In studies with little or no effect of weight loss on inflammatory outcomes ([@B24]; [@B28]), it may be that the initial level of obesity was not sufficient for inducing systemic and/or local inflammation in subcutaneous adipose tissue. Certainly, in subjects with *obesity* and *morbid obesity*, weight loss by diet ([@B11]; [@B9]; [@B8]) and/or exercise ([@B3]; [@B7]) and bariatric surgery ([@B4]) drastically reduces pro-inflammatory cytokines in serum and mRNA expression of adipokines in subcutaneous adipose tissue. We speculate that the healthy overweight subjects in our cohort who never had a BMI greater than 32 kg/m^2^ did not have obesity-induced low-grade inflammation from the outset, thereby leading to a negative finding for diet and exercise mediated improvements in inflammation. It has been hypothesized that fasting/feeding cycles induce low-level inflammatory responses in metabolic cells from lean animals, and it is only when chronic nutrient excess occurs that the inflammatory response reaches a certain threshold and a more harmful inflammatory response is activated ([@B16]). Indeed, even 8 weeks of overfeeding (3200--5800 kJ/day) in lean to overweight individuals resulting in 3--4% weight gain is not sufficient to alter circulating and local inflammation markers ([@B31]; [@B1]). Furthermore, the baseline CRP levels in this study were considerably lower than CRP levels described in morbidly obese subjects (2--6 mg/l; [@B21]; [@B20]). Coupled with the findings in the current study, it may be that a threshold of weight gain/loss is required for inflammation to be induced, or reversed.

Obesity-induced inflammation is especially present when adiposity is in the visceral depot ([@B2]) since several inflammatory markers such as PAI-1, MIF, CCL2 are preferentially expressed in visceral fat ([@B14]). Given that the inflammatory state in obesity is not improved by removal of subcutaneous fat with liposuction ([@B23]), a reduction of visceral fat in diet and exercise studies is probably most important ([@B6]). Therefore, measuring the expression of genes in the visceral fat, albeit impossible in most clinical studies, may provide further insights into the effects of diet and/or exercise on low-grade inflammation in overweight individuals. A limitation of our study is the relatively low sample size as our analysis was an exploratory end point of the parent study. Nevertheless, the sample size of this study was similar to previously published studies looking at the effects of diet and/or exercise interventions on inflammation ([@B14]).

In summary, our data indicates that even with a 10% weight loss and 30% reduction in visceral fat, there was no marked improvement in systemic or markers of inflammation in subcutaneous adipose tissue probably due to the general good health of our overweight and not obese participants.
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